Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway - Quiz - MDSpire

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • By

  • Biao Zheng

  • Guojun Yao

  • Yuli Pang

  • Jielong Luo

  • Zhiyong Yang

  • Fengmin Xiu

  • Chaohui Zhen

  • Rui Liang

  • June 9, 2026

  • 0 min

Share

Original Source(s)

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

  • June 9, 2026

Related Content

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies

Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary in vivo validation

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review